Idarubicin en es it fr

Idarubicin Brand names, Idarubicin Analogs

Idarubicin Brand Names Mixture

  • No information avaliable

Idarubicin Chemical_Formula


Idarubicin RX_link

Idarubicin fda sheet

Idarubicin FDA

Idarubicin msds (material safety sheet)

Idarubicin Synthesis Reference

No information avaliable

Idarubicin Molecular Weight

497.494 g/mol

Idarubicin Melting Point

No information avaliable

Idarubicin H2O Solubility

No information avaliable

Idarubicin State


Idarubicin LogP


Idarubicin Dosage Forms

Powder for solution

Idarubicin Indication

For the treatment of acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7.

Idarubicin Pharmacology

Idarubicin is an antineoplastic in the anthracycline class. General properties of drugs in this class include: interaction with DNA in a variety of different ways including intercalation (squeezing between the base pairs), DNA strand breakage and inhibition with the enzyme topoisomerase II. Most of these compounds have been isolated from natural sources and antibiotics. However, they lack the specificity of the antimicrobial antibiotics and thus produce significant toxicity. The anthracyclines are among the most important antitumor drugs available. Doxorubicin is widely used for the treatment of several solid tumors while daunorubicin and idarubicin are used exclusively for the treatment of leukemia. Idarubicin may also inhibit polymerase activity, affect regulation of gene expression, and produce free radical damage to DNA. Idarubicin possesses an antitumor effect against a wide spectrum of tumors, either grafted or spontaneous. The anthracyclines are cell cycle-nonspecific.

Idarubicin Absorption

No information avaliable

Idarubicin side effects and Toxicity

No information avaliable

Idarubicin Patient Information

No information avaliable

Idarubicin Organisms Affected

Humans, other mammals and bacteria